Apeiron acquires rights to new clinical stage project

APEIRON Biologics AG (Apeiron) today announced that, as part of its effort to broaden its current project portfolio, it has concluded an agreement with Polymun Scientific GmbH (Polymun) granting Apeiron exclusive rights to recombinant human Super Oxide Dismutase (SOD) for treatment of various inflammatory conditions. Press release Presseaussendung  

November 4, 2010
View the Post